Sunset Beauty Elements Stills Young adult women outdoors in Colorado Beautiful Females from various angles, DOF and POV Lens Flare and Backlight Intentional(photos professionally retouched and filters applied as needed - Lightroom / Photoshop - original size 8688 x 5792 canon 5DS Full Frame)

EndoPredict Breast Cancer Prognostic Test

The most accurate second generation gene expression test for early-stage breast cancer,1 proven to predict each patient’s risk of early and long-term breast cancer recurrence and guide chemotherapy decisions.

How to predict recurrence of early-stage breast cancer

The most accurate decision making tool for breast cancer treatment decisions

Genomic testing for breast cancer recurrence is guiding critical treatment decision making in early‑stage breast cancer patients, and helping clinicians avoid over and under treatment.

Myriad Genetics’ EndoPredict® Breast Cancer Prognostic Test is a genomic test for breast cancer that accurately predicts the risk of breast cancer recurrence (return) up to 15 years and an individual’s benefit from chemotherapy,2,3 helping to guide key treatment decisions for every eligible woman with early-stage ER positive/HER2 negative breast cancer.

EndoPredict uses molecular biology and clinical pathological factors to help answer critical treatment questions:

Will adjuvant chemotherapy be needed?

EndoPredict is the most accurate prognostic test to guide early treatment decisions, providing an individual risk of breast cancer recurrence at 10 years.1,4

Will chemotherapy be of benefit?

Some women will benefit more from chemotherapy than others – EndoPredict provides the personalized chemobenefit for every patient to guide decision making.3

Will extended endocrine therapy be needed?

EndoPredict is the only test to predict breast cancer recurrence risk up to 15 years, helping clinicians decide if extended endocrine therapy is needed.2

 

Watch Myriad Genetics' ESMO 2022 Industry Satellite Symposium

Should we use genetic signatures for chemotherapy decisions in ER+/HER2- premenopausal patients? Dr. Anastasia Constantinidou shares key new data from ESMO Congress 2022 demonstrating how EndoPredict can help guide treatment decisions and avoid overtreatment for premenopausal women with ER+, HER2- early breast cancer.

Watch video

How can the EndoPredict test help you?

A concerned female doctor reviews a senior female patient's troubling test results.

Who is eligible for the EndoPredict test?

EndoPredict gives important information to guide early treatment decisions for women with invasive primary breast cancer that is:

  • HER2 negative
  • ER positive
  • Lymph node positive or negative
  • Pre- and postmenopausal
  • Tumour size pT1 to pT3
  • Grade 1 to 3

EndoPredict is the only second generation gene expression test for breast cancer validated in premenopausal AND postmenopausal women who are lymph node positive or node negative2-8 – and the first with level of evidence 1A data,9,10 for confident treatment decisions.

Why is the EndoPredict test so accurate?

EndoPredict is a second generation test that incorporates more than other tests

EndoPredict combines three factors – a molecular score, tumor size and nodal status – to give the EPclin Risk Score. The result is more prognostic information than first generation tests and assays that only measure gene expression, or clinical pathological factors alone.

The test has been developed and validated to include genes that predict both early and late recurrence (0-15 years). These improve prognostic value of EndoPredict compared with classical prognostic factors and first generation tests.1,5,6

Learn more about EndoPredict’s superior accuracy here.

The EndoPredict test can be performed locally within a few days

The EndoPredict breast cancer prognosis test is a CE-marked in vitro diagnostic (IVD) test. It can be performed in local molecular pathology laboratories. The results are available within a few days and the test cost refund is assured for eligible patients in many countries.

How to order EndoPredict

Clinicians

EndoPredict is available to order by clinicians via numerous local labs in your country or outside of the EU also via Myriad Genetics’ central laboratory in Salt Lake City, USA.

Pathologists

EndoPredict is available as a CE-marked IVD kit that can be run in local molecular pathology laboratories after a comprehensive onsite training, provided by Myriad Genetics.

Contact us

Contact us for more information on EndoPredict. Whether you are a clinician, pathologist or patient, you can send us a message below through our easy-to-use contact form.
You can also reach us by email at info@myriadgenetics.eu.

We are committed to providing genetic insights that advance the health and wellbeing of every woman.

References

  1. Sestak, Ivana et al. “Comparison Of The Performance Of 6 Prognostic Signatures For Estrogen Receptor–Positive Breast Cancer“. JAMA Oncology, vol 4, no. 4, 2018, pp. 545-553
  2. Filipits, Martin et al. “Prediction Of Distant Recurrence Using Endopredict Among Women With ER+, HER2− Node-Positive And Node-Negative Breast Cancer Treated With Endocrine Therapy Only“. Clinical Cancer Research, vol 25, no. 13, 2019, pp. 3865-3872
  3. Sestak, Ivana et al. “Prediction Of Chemotherapy Benefit By Endopredict In Patients With Breast Cancer Who Received Adjuvant Endocrine Therapy Plus Chemotherapy Or Endocrine Therapy Alone“. Breast Cancer Research And Treatment, vol 176, no. 2, 2019, pp. 377-386
  4. Filipits, Martin et al. “A New Molecular Predictor Of Distant Recurrence In ER-Positive, HER2-Negative Breast Cancer Adds Independent Information To Conventional Clinical Risk Factors“. Clinical Cancer Research, vol 17, no. 18, 2011, pp. 6012-6020
  5. Buus, Richard et al. “Comparison Of Endopredict And Epclin With Oncotype DX Recurrence Score For Prediction Of Risk Of Distant Recurrence After Endocrine Therapy“. Journal Of The National Cancer Institute, vol 108, no. 11, 2016, p. djw149
  6. Dubsky, Peter et al. “The Endopredict Score Provides Prognostic Information On Late Distant Metastases In ER+/HER2− Breast Cancer Patients“. British Journal Of Cancer, vol 109, no. 12, 2013, pp. 2959-2964
  7. Martin, Miguel et al. “Clinical Validation Of The Endopredict Test In Node-Positive, Chemotherapy-Treated ER+/HER2− Breast Cancer Patients: Results From The GEICAM 9906 Trial“. Breast Cancer Research, vol 16, no. 2, 2014, p. R38
  8. Constantinidou, Anastasia, et al. “Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer”. Clinical Cancer Research, vol. 28, no. 20, 2022, pp. 4435–4443
  9. Simon, Richard et al. “Use Of Archived Specimens In Evaluation Of Prognostic And Predictive Biomarkers”. Journal Of The National Cancer Institute, vol 101, no. 21, 2009, pp. 1446-1452
  10. Penault-Llorca, Frederique et al. “Prognostic value of EndoPredict test in patients screened for UNIRAD, a UCBG randomized, double blind, phase III international trial evaluating the addition of *** (EVE) to adjuvant hormone therapy (HT) in women with high risk HR+, HER2- early breast cancer (eBC)“. SABCS 2021, PD-09-08 Spotlight Poster Discussion 9